Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.

Theranostics - 1 Jan 2020

Li Hongyi, Tu Jian, Zhao Zhiqiang, Chen Lijuan, Qu Yueting, Li Hongbo, Yao Hao, Wang Xiaoshuai, Lee Dung-Fang, Shen Jingnan, Wen Lili, Huang Gang, Xie Xianbiao

Abstract excerpt

Background: Patients with advanced soft tissue sarcomas (STS) have a dismal prognosis with few effective therapeutic options. A defect in the homologous recombination repair (HRR) pathway can accumulate DNA repair errors and gene mutations, which can lead to tumorigenesis. BRCAness describes tumors with an HRR deficiency (HRD) in the absence of a germline BRCA1/2 mutation. However, the characteristics of BRCAness...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Copy Number Variations
Share to Indazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Piperidines

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Recombinational DNA Repair

Share to Sarcoma

Source

Open in PubMed Open full text

Identifiers

PMID: 32863940
DOI: 10.7150/thno.45763
PMCID: PMC7449912

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.PMID 32863940Read ↗

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic targetSemantic proximity Read ↗

Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients.Semantic proximity Read ↗

Transcriptomic-Based Classification Identifies Prognostic Subtypes and Therapeutic Strategies in Soft Tissue SarcomasSemantic proximity Read ↗

Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcomaSemantic proximity Read ↗

DNA methylation patterns–based subtype distinction and identification of soft tissue sarcoma prognosisSemantic proximity Read ↗

A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosisSemantic proximity Read ↗

Derivation, Comprehensive Analysis of Cancer-associated Fibroblasts and Their Correlation to Prognosis, Immune Status and Drug Sensitivity in Patients of Soft Tissue SarcomaSemantic proximity Read ↗

Targetable Alterations in Adult Patients With Soft-Tissue SarcomasSemantic proximity Read ↗

Identification of anoikis-related molecular patterns to define tumor microenvironment and predict immunotherapy response and prognosis in soft-tissue sarcomaSemantic proximity Read ↗

Retrospective Analysis of BRCA -Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase InhibitorsSemantic proximity Read ↗

Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trialSemantic proximity Read ↗

Identification and Validation of a Novel Pyroptosis-Related Gene Signature for Prognosis Prediction in Soft Tissue SarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.